Head-to-head · Value Score
CoreAge Rx vs LumiMeds
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, LumiMeds a 73. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameLumiMeds
#173 · Grade C+ · Watch List
Est. first month
From $89/mo (lowest rate needs a longer plan, compounded)
Save ~93% vs brand-nameFDA warning letter. The FDA issued Lumimeds a warning letter in September 2025. Check it on the FDA database.
Get this deal Full LumiMeds review →The verdict
CoreAge Rx takes it on Value Score, 93 to 73 — an est. $99/mo first month, with no teaser step-up baked in. LumiMeds isn't out of it: Someone chasing the lowest published rate who is willing to commit to a longer plan for it.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | LumiMeds |
|---|---|---|
| Value Score | 93 (A+) | 73 (C+) |
| Est. first month | $99/mo | From $89/mo (lowest rate needs a longer plan, compounded) |
| Save vs brand-name | ~89% | ~93% |
| Semaglutide | $99/mo | From $89/mo (lowest rate needs a longer plan, compounded) |
| Tirzepatide | $149/mo | From $125/mo (lowest rate needs a longer plan, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | All 50 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
LumiMeds
LumiMeds is a LegitScript-certified telehealth practice licensed in all 50 states, selling compounded semaglutide from $89 and compounded tirzepatide from $125 a month with no membership fee, prescribed by a physician board-certified in obesity medicine.
Why it's a deal
- Among the lowest published rates tracked here — $89 semaglutide and $125 tirzepatide — with no membership fee layered on top
- LegitScript certified and licensed in all 50 states, with a prescriber board-certified in obesity medicine named on the site
- HSA and FSA eligible, and the medication is dispensed from a 503A pharmacy on a per-prescription basis
- Plan lengths are shown as a ladder rather than a single take-it-or-leave-it commitment
The fine print
- $89 is the bottom of a plan ladder, not a month-to-month rate — the monthly option costs more, and the site does not put that figure beside the headline
- The longest plans are paid as a block, so the cheapest rate is also the hardest to walk away from
- Compounded only — no FDA-approved brand-name route
- Results claims lean on aggregate member counts rather than published methodology
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to LumiMeds.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.